{
    "clinical_study": {
        "@rank": "134694", 
        "brief_summary": {
            "textblock": "The purpose of this study is to see if it is safe and effective to give PMPA to HIV-infected\n      patients. This study also examines how the body handles PMPA."
        }, 
        "brief_title": "A Study of PMPA in HIV-Infected Patients", 
        "condition": "HIV Infections", 
        "condition_browse": {
            "mesh_term": [
                "HIV Infections", 
                "Acquired Immunodeficiency Syndrome"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria\n\n        Patients must have:\n\n          -  Laboratory diagnosis of HIV infection.\n\n          -  CD4 cell count >= 200 cells/mm3 within 28 days prior to entry.\n\n          -  Plasma HIV RNA >= 10,000 copies/ml within 28 days of entry.\n\n          -  Minimum life expectancy of 12 months.\n\n        Exclusion Criteria\n\n        Co-existing Condition:\n\n        Patients with any of the following symptoms or conditions are excluded:\n\n          -  Active, serious infections (other than HIV) that require parental antibiotic therapy.\n             Patients may be considered recovered if at least 2 weeks have elapsed following\n             cessation of parental therapy before enrollment.\n\n          -  Active clinically significant medical problems that include cardiac disease (e.g.,\n             symptoms of ischemia, congestive heart failure, or arrhythmia).\n\n          -  Positive test for Hepatitis B surface antigen or Hepatitis C antibody in serum.\n\n        Patients with any of the following prior conditions are excluded:\n\n        History of malignancy other than basal cell carcinoma or cutaneous Kaposi's sarcoma.\n\n        Patients who are receiving:\n\n          -  Antiretroviral therapy, including nucleoside analogs, non-nucleoside reverse\n             transcriptase inhibitors, protease inhibitors or investigational antiretroviral\n             agents.\n\n          -  Interferon or interleukin therapy, aminoglycoside antibiotics, amphotericin B,\n             cidofovir, diuretics, foscarnet, ganciclovir, itraconazole, fluconazole, ketoconazole\n             (topical allowed), isoniazid, rifampin, rifabutin, clarithromycin, azithromycin,\n             systemic chemotherapeutic agents, systemic corticosteroids, other agents with\n             significant nephrotoxic potential, other agents that may inhibit or compete for\n             elimination via active renal tubular secretion (probenecid) and other investigational\n             agents.\n\n        Within 2 weeks prior to entry:\n\n          -  Antiretroviral therapy, including nucleoside analogs, non-nucleoside reverse\n             transcriptase inhibitors, protease inhibitors or investigational antiretroviral\n             agents.\n\n          -  Interferon or interleukin therapy, aminoglycoside antibiotics, amphotericin B,\n             cidofovir, diuretics, foscarnet, ganciclovir, itraconazole, fluconazole, ketoconazole\n             (topical allowed), isoniazid, rifampin, rifabutin, clarithromycin, azithromycin,\n             systemic chemotherapeutic agents, systemic corticosteroids, other agents with\n             significant nephrotoxic potential, other agents that may inhibit or compete for\n             elimination via active renal tubular secretion (probenecid) and other investigational\n             agents.\n\n        Active drug or alcohol abuse as demonstrated by a positive screening test for drugs of\n        abuse (except marijuana or drugs used for medical indications), or substance abuse\n        considered sufficient to hinder patient compliance."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "firstreceived_date": "November 2, 1999", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00002180", 
            "org_study_id": "269A", 
            "secondary_id": "GS-96-701"
        }, 
        "intervention": {
            "intervention_name": "Tenofovir", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": "Tenofovir"
        }, 
        "keyword": [
            "Placebos", 
            "Anti-HIV Agents", 
            "Adenine"
        ], 
        "lastchanged_date": "June 23, 2005", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "San Francisco", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "94110"
                    }, 
                    "name": "San Francisco Gen Hosp / AIDS Program"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Baltimore", 
                        "country": "United States", 
                        "state": "Maryland", 
                        "zip": "21205"
                    }, 
                    "name": "Johns Hopkins Univ"
                }
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "official_title": "A Phase I/II Randomized, Double-Blind, Placebo-Controlled Study of the Safety, Tolerance, and Pharmacokinetics, and Antiviral Activity of 9-[(R)-2-(Phosphonomethoxy)Propyl] Adenine (PMPA) in HIV-Infected Patients", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "Phase 1", 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00002180"
        }, 
        "source": "NIH AIDS Clinical Trials Information Service", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Gilead Sciences", 
                "agency_class": "Industry"
            }
        }, 
        "study_design": "Endpoint Classification: Pharmacokinetics Study, Masking: Double-Blind, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "September 1999"
    }, 
    "geocoordinates": {
        "Johns Hopkins Univ": "39.29 -76.612", 
        "San Francisco Gen Hosp / AIDS Program": "37.775 -122.419"
    }
}